ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records

Share Article

ProSanos Corporation announced today the release of SÆfetyworks™, a web-based, semi-automated software system that can help scientists more quickly spot and measure the strength of associations between a drug and a medical condition found within large electronic healthcare databases. SÆfetyworks™ resulted from a partnership between GlaxoSmithKline plc (GSK) and ProSanos. Several years in development, it is now available to all pharmacovigilance professionals.

News Image
In a post-market environment, robust well-designed technologies like SÆfetyworks™ can be an important part of the solution to the challenges of drug safety surveillance. ProSanos looks forward to deploying the system with other participants in the process, so that even larger numbers of patients might benefit.

The new software system, pioneered by GSK and ProSanos, is an efficient way to perform active drug surveillance and complement traditional epidemiologic studies. Using SÆfetyworks™, drug safety experts will have the unprecedented ability to ask the same questions of different databases. Data from traditional sources, like adverse event reports and epidemiological studies, can quickly and reliably be compared with information from observational sources like insurance claims and electronic medical records. In addition, pharmacovigilance professionals will be able to control for multiple confounding factors, helping them to quickly distinguish unusual conditions that may be associated with a drug from conditions that are disease-related or limited to specific cohorts of patients.

Commenting on the co-development collaboration with ProSanos, Edward Pattishall, MD, VP Safety at GSK stated, "GSK is committed to enhancing patient safety and anticipates this tool will be extremely helpful in evaluating the benefit/risk profile of our medicines using multiple data sources that can't currently be easily and quickly compared.

It is an improvement over other software solutions because it can rapidly and simultaneously interrogate multiple databases and contribute to the evidence of a potential safety issue. We have made an up-front investment in developing this tool and we hope that others will benefit as enhancing patient safety is a common goal for everyone involved in the manufacture, administration and regulation of medicines."

Jonathan Morris, M.D., President and CEO of ProSanos Corporation, said, "In a post-market environment, robust well-designed technologies like SÆfetyworks™ can be an important part of the solution to the challenges of drug safety surveillance. ProSanos looks forward to deploying the system with other participants in the process, so that even larger numbers of patients might benefit."

About ProSanos Corporation

The mission of ProSanos Corporation (http://www.prosanos.com) is to advance patient safety and care by providing clients and partners with superior products and services for the integration, analysis and management of healthcare-related data. Founded in 2000 and known for its innovative approach to the analysis and mining of healthcare data, the company provides products and services that promote in-depth understanding of the treatment of specific diseases and conditions. ProSanos Corporation is headquartered in Harrisburg, PA.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michele Washko
Visit website